Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation

J Med Chem. 2012 Apr 12;55(7):3285-306. doi: 10.1021/jm201734r. Epub 2012 Mar 26.

Abstract

Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer metabolism. In this manuscript we report our progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors. Fragment hits were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking. Also reported is their modification into cellular active compounds suitable for target validation work.

MeSH terms

  • Animals
  • Catalytic Domain
  • Cell Line, Tumor
  • Crystallography, X-Ray
  • Drug Design
  • Enzyme Assays
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • L-Lactate Dehydrogenase / antagonists & inhibitors*
  • Lactate Dehydrogenase 5
  • Magnetic Resonance Spectroscopy
  • Malonates / chemical synthesis
  • Malonates / chemistry
  • Malonates / pharmacology
  • Models, Molecular
  • Molecular Structure
  • Niacinamide / chemistry
  • Oxamic Acid / analogs & derivatives
  • Oxamic Acid / chemical synthesis
  • Oxamic Acid / chemistry
  • Oxamic Acid / pharmacology
  • Protein Binding
  • Rats
  • Structure-Activity Relationship
  • Surface Plasmon Resonance

Substances

  • Isoenzymes
  • Malonates
  • Niacinamide
  • L-Lactate Dehydrogenase
  • Lactate Dehydrogenase 5
  • Oxamic Acid

Associated data

  • PDB/4AJ1
  • PDB/4AJ2
  • PDB/4AJ4
  • PDB/4AJE
  • PDB/4AJH
  • PDB/4AJI
  • PDB/4AJJ
  • PDB/4AJK
  • PDB/4AJL
  • PDB/4AJO
  • PDB/4AJP
  • PDB/4AL4